Home
Clinical Resources Search
PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Download PQI pdf 0.18MB

Last Updated: June 4, 2024

By: Kathleen Burns, MSN, NP

About this PQI

This document will help in the initiation and management of patients taking talazoparib in combination with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer.

More About This PQI

PQI:

Enzalutamide-Xtandi-In-Castration-Resistant-Prostate-Cancer-or-Metastatic-Castration-Sensitive-Prostate-Cancer_PQI_NCODA pdf 0.18MB

PQI in Action Articles:

Enzalutamide_Xtandi_Prostate pdf 1.21MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Prostate Cancer Enzalutamide Talazoparib Talzenna Xtandi

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

About this PQI

More About This PQI

PQI:

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI: Radium Ra 223 Dichloride (Xofigo®) Management

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: Enzalutamide (Xtandi®) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

PQI in Action: Enzalutamide (Xtandi®) in Castration Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

PQI: PARP Inhibitor Eligibility in Ovarian Cancer